Literature DB >> 15218973

Significance of decreased plasma D-dimer levels following lipopolysaccharide-induced disseminated intravascular coagulation in rats.

Hidesaku Asakura1, Yoko Sano, Mika Omote, Tomotaka Yoshida, Yasuo Ontachi, Tomoe Mizutani, Minori Kaneda, Masahide Yamazaki, Eriko Morishita, Akiyoshi Takami, Ken-ichi Miyamoto, Shinji Nakao.   

Abstract

Plasma D-dimer (DD) is considered to be one of the most useful markers in the diagnosis and assessment of disseminated intravascular coagulation (DIC). The present study was performed to clarify the role of DD in a rat model of lipopolysaccharide (LPS)-induced DIC in which low-molecular-weight heparin (LMWH) and tranexamic acid (TA) were used. We investigated whether a relationship exists between plasma DD levels and severity of DIC. Experimental DIC was induced in rats by a sustained 4-hour infusion of 30 mg/kg LPS administered via the tail vein (LPS group). Rats received either LPS alone (LPS group) or LPS combined with 200 U/kg LMWH (LPS+LMWH group) or 50 mg/kg TA (LPS+TA group) from -30 minutes to 4 hours. Blood was drawn from each rat at 4, 8, and 12 hours. Plasma levels of thrombin-antithrombin complex (TAT) and creatinine were suppressed in the LPS+LMWH group, and less glomerular fibrin deposition was observed compared with the LPS group. On the other hand, an increased level of creatinine and increased glomerular fibrin deposition were observed in the LPS+TA group compared with the LPS group. LMWH demonstrated a protective effect against LPS-induced DIC, resulting in increased survival at 12 hours, whereas TA had the opposite effect. From these results, it appears that LMWH protects against LPS-induced DIC, but TA exacerbates LPS-induced DIC. It was interesting that plasma levels of DD were almost completely suppressed by concurrent administration of either TA or LMWH in this LPS-induced DIC model. This finding suggested that plasma levels of DD were suppressed by inhibition of coagulation (reduced deposition of fibrin) in the LPS+LMWH group and that DD levels were also suppressed by inhibition of fibrinolysis (reduced degradation of fibrin by plasmin) in the LPS+TA group. Thus care should be taken when evaluating the significance of plasma DD levels, because suppressed levels can occur with progressive fibrin deposition and worsening organ dysfunction or improvement in the course of DIC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15218973     DOI: 10.1532/ijh97.03168

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  24 in total

1.  Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.

Authors:  F B Taylor; C H Toh; W K Hoots; H Wada; M Levi
Journal:  Thromb Haemost       Date:  2001-11       Impact factor: 5.249

2.  An immunological method for demonstrating fibrin degradation products in serum and its use in the diagnosis of fibrinolytic states.

Authors:  H C FERREIRA; L G MURAT
Journal:  Br J Haematol       Date:  1963-07       Impact factor: 6.998

3.  Protective effects of DX-9065a, an orally active, novel synthesized and selective inhibitor of factor Xa, against thromboplastin-induced experimental disseminated intravascular coagulation in rats.

Authors:  M Yamazaki; H Asakura; K Aoshima; M Saito; H Jokaji; C Uotani; I Kumabashiri; E Morishita; T Ikeda; T Matsuda
Journal:  Semin Thromb Hemost       Date:  1996       Impact factor: 4.180

Review 4.  Disseminated intravascular coagulation: pathophysiological mechanisms and manifestations.

Authors:  R L Bick
Journal:  Semin Thromb Hemost       Date:  1998       Impact factor: 4.180

Review 5.  Regulation of inflammatory responses by natural anticoagulants.

Authors:  K Okajima
Journal:  Immunol Rev       Date:  2001-12       Impact factor: 12.988

6.  Acquired alpha-2-antiplasmin deficiency in acute promyelocytic leukaemia.

Authors:  G Avvisati; J W ten Cate; A Sturk; R Lamping; M G Petti; F Mandelli
Journal:  Br J Haematol       Date:  1988-09       Impact factor: 6.998

7.  Heterogeneity in the incidence and clinical manifestations of disseminated intravascular coagulation: a study of 204 cases.

Authors:  K Okajima; Y Sakamoto; M Uchiba
Journal:  Am J Hematol       Date:  2000-11       Impact factor: 10.047

8.  Plasminogen activators and their inhibitors in leukemic cell homogenates.

Authors:  H Wada; Y Kumeda; Z Ogasawara; M Ohiwa; T Kaneko; S Tamaki; T Ohno; S Kageyama; T Kobayashi; K Deguchi
Journal:  Am J Hematol       Date:  1993-02       Impact factor: 10.047

9.  Induction of vasoactive substances differs in LPS-induced and TF-induced DIC models in rats.

Authors:  Hidesaku Asakura; Mariko Okudaira; Tomotaka Yoshida; Yasuo Ontachi; Masahide Yamazaki; Eriko Morishita; Ken-ichi Miyamoto; Shinji Nakao
Journal:  Thromb Haemost       Date:  2002-10       Impact factor: 5.249

10.  Measurement of cross linked fibrin derivatives in plasma: an immunoassay using monoclonal antibodies.

Authors:  A N Whitaker; M J Elms; P P Masci; P G Bundesen; D B Rylatt; A J Webber; I H Bunce
Journal:  J Clin Pathol       Date:  1984-08       Impact factor: 3.411

View more
  2 in total

1.  Consideration of Tranexamic Acid Administration to COVID-19 Patients.

Authors:  Haruhiko Ogawa; Hidesaku Asakura
Journal:  Physiol Rev       Date:  2020-10-01       Impact factor: 37.312

2.  Recombinant human erythropoietin attenuates hepatic dysfunction by suppressing hepatocellular apoptosis in lipopolysaccharide-induced disseminated intravascular coagulation in rats.

Authors:  Yukio Suga; Fumio Akita; Shinya Yamada; Eriko Morishita; Hidesaku Asakura
Journal:  Biomed Rep       Date:  2021-11-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.